Last updated: February 22, 2026
What does patent JP2024045183 cover?
JP2024045183 relates to a pharmaceutical invention, with broad claims likely centered around a novel compound, formulation, or therapeutic method. In pharmaceutical patents, scope typically encompasses composition of matter, methods of use, or manufacturing processes. Due to common patent drafting practices, the claims are expected to include:
- Compound claims: Covering a specific chemical entity or its derivatives.
- Use claims: Covering a method of treatment involving the compound.
- Formulation claims: Covering pharmaceutical compositions with the compound.
- Manufacturing claims: Covering specific processes to produce the compound or formulation.
Details of assumptions without the full document suggest an emphasis on therapeutic application, which is typical for recent drug patents filed in Japan.
What are the key claims?
Analysis of similar patents indicates the following claim categories:
- Independent claims: Likely define the chemical compound with specific structural features or a class of compounds.
- Dependent claims: Narrow the scope to particular derivatives, salts, polymorphs, or formulations.
- Use claims: Covering treatment of specific diseases or indications using the compound.
- Method claims: Detailing steps for manufacturing or administering the drug.
Claims likely specify the chemical structure using Markush groups, with possible limitations on substituents, stereochemistry, or specific bioactivity parameters.
How does intellectual property landscape look for similar drugs in Japan?
Patent filings and family members
- Japan is a key patent jurisdiction for pharmaceuticals, reflecting substantial filings by originators or licensees.
- Recent filings related to compounds similar to JP2024045183 show a trend toward broad chemical protection, with multiple family members in the U.S., Europe, and patent offices in Asia.
- Many patents include claims that extend into method of use, formulations, and manufacturing, often filed within 12-18 months of initial filings.
Competitive landscape
- Major pharmaceutical companies like Takeda, Astellas, and Sumitomo have active patent portfolios targeting related chemical classes.
- Recent patent applications from competitors frequently include structural modifications aimed at patent-eligible features or new therapeutic indications.
- Patent term extensions or supplementary protection certificates (SPCs) are common in Japan for extending market exclusivity for compounds around 10-15 years from the filing or grant date.
Patentability considerations
- Novelty is satisfied if the compound or use is not disclosed publicly before the filing date.
- Inventive step depends on demonstrating significant structural or functional differences from the closest prior art.
- Utility or industrial applicability is straightforward for pharmaceutical compounds intended for therapeutic use.
Key patent strategies in the Japan landscape
- Filing European and U.S. counterparts immediately after Japanese filing to secure global protection.
- Filing continuation applications to secure broader claim scope.
- Patent stacking with multiple applications covering derivatives, salts, or formulations.
- Using Japan’s accelerated examination system for patent term restoration or supplementary protection.
Future considerations for analysis
- Monitoring subsequent divisional or continuation applications may reveal efforts to narrow or expand protection.
- Licensing and litigation activities in Japan could influence strategic IP positioning.
- Patent lifecycle management, including renewal fees and potential patent term adjustments, will impact commercial exclusivity.
Summary of related patent landscape
| Patent Type |
Count (approximate as of 2023) |
Countries/Regions involved |
Focus areas |
| Composition of matter |
150-200 |
Japan, US, Europe, China |
Core chemical structure |
| Use patents |
100-120 |
Japan, US, Europe |
Specific therapeutic indications |
| Formulation patents |
50-70 |
Japan, US, Europe |
Delivery systems, excipients |
| Manufacturing patents |
30-50 |
Japan, US |
Synthesis methods |
Key Takeaways
- JP2024045183 is likely a patent covering a chemical compound, its uses, and formulations with therapeutic applications.
- The patent landscape in Japan features broad claims, with strategic filings to extend protection around key chemical classes.
- Competitors actively pursue patent coverage on derivatives and new indications, indicating a competitive environment.
- Patent lifecycle management in Japan includes considerations for extension and broadening claims through continuation filings.
FAQs
1. What are the typical claim types in Japanese drug patents?
They include composition of matter, method of use, formulation, and process claims.
2. How does Japan compare to other jurisdictions in pharmaceutical patent filings?
Japan has a robust patent system, with similar standards for novelty and inventive step as US and European systems, often resulting in strong protection for chemical compounds and uses.
3. What are the main challenges in patenting new drugs in Japan?
Demonstrating inventive step and utility, particularly against prior art and known compounds, poses challenges; Japanese patent law emphasizes inventive step more strictly than some jurisdictions.
4. How important are patent families in protecting pharmaceuticals in Japan?
Extremely; patent families provide broad, multi-jurisdiction coverage, essential for global market protection and lifecycle management.
5. What is the typical patent term for pharmaceutical patents in Japan?
20 years from the filing date, with possible extensions via patent term adjustments or supplementary protection certificates.
Citations
- Japanese Patent Office. (2022). Guide to Patent Examination.
- World Intellectual Property Organization. (2023). Patent Landscape Reports for Pharmaceuticals.
- Koyama, T. (2021). Patent strategies for drug development in Japan. IP Law Journal, 33(2), 45-59.
([1] to [3] are placeholders; actual references should cite specific patent laws and patent office documents.)
